Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:China
|
| gptkbp:founded |
2003
|
| gptkbp:headquarters_location |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sinopharm Group Co. Ltd.
|
| gptkbp:industry |
healthcare
pharmaceuticals |
| gptkbp:keyPerson |
Li Zhiming
|
| gptkbp:listedOn |
gptkb:Fortune_Global_500
|
| gptkbp:notableProduct |
gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:Sinopharm_WIBP_COVID-19_vaccine |
| gptkbp:numberOfEmployees |
over 100,000
|
| gptkbp:parentOrganization |
gptkb:China_National_Pharmaceutical_Group
|
| gptkbp:products |
medical devices
vaccines pharmaceutical distribution |
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:1099.HK
|
| gptkbp:website |
http://www.sinopharm.com/
|
| gptkbp:bfsParent |
gptkb:1099.HK
|
| gptkbp:bfsLayer |
7
|